Navigation Links
Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
Date:4/29/2010

atories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 in the U.S. and Canada.    

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.  

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial.  Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia.  More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties.  Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs.  The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statem
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
2. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
3. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
4. Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
5. Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
6. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
7. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
8. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
9. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 21, 2014   BioNano Genomics , the ... research centers to purchase an Irys™ System . ... Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) and ... obtaining a comprehensive view of a genome was ... does not deliver the scalability or reliability to ...
(Date:10/22/2014)... Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Second quarter overview: , Revenues of $53.9 million, ... Diluted EPS of $0.24, up 33% over last year,s ... revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 ...
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... , , FRANKLIN LAKES, N.J., Jan. 11 ... announced today that it will conduct a live webcast of its ... 2010 at 10:00 a.m. (ET). BD will issue a press ... of the conference call, along with related slides, will be accessible ...
... Calif., Jan. 11 Finesse Solutions, LLC, a manufacturer ... applications, announced the production release of its single-use sensor ... and process temperature, and TruTorr headspace pressure sensors. ... ease of use. It is available on the Thermo ...
Cached Medicine Technology:BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call 2Single-Use Sensor Product Family Enters High Volume Production 2
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
(Date:10/22/2014)... By Amy Norton ... -- Headlines remain riveted on the three Ebola cases in ... much bigger health threat to Americans. President Barack Obama ... response to the virus, which has infected two Dallas nurses ... this month at Texas Health Presbyterian Hospital. But the ...
(Date:10/22/2014)... Angeles, California (PRWEB) October 22, 2014 Hay ... 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) ... field of Yoga & Recovery. This book is meant ... thrive in a life of recovery. , Recovery 2.0 ... the 12 Steps; Recovery 2.0 is a guide for what ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... estimated 15,000 - 20,000,members, ATLANTA, Dec. 4 ... week, to accommodate its growing membership in,DeKalb County ... ceremony for the new Stonecrest Medical Center was ... Ramsey, Georgia State,Representative Stan Watson, DeKalb County Commissioner ...
... The National,Organization of Life & Health Insurance Guaranty ... associations that are playing,a central role in the ... Company of New York (ELNY) matter., NOLHGA ... the ELNY situation: "NOLHGA and all of our ...
... antibiotics and nasal steroids don,t lessen symptoms , , TUESDAY, ... work no better than a placebo in combating sinus ... probably not as effective as have been previously believed, ... said study author Dr. Ian Williamson, a senior lecturer ...
... BMIs experience a significant survival benefit from liver ... transplant compared to patients with normal BMI. Therefore, ... listed for transplantation, say the authors of a ... a journal by John Wiley & Sons. The ...
... and heart,s electrical system , , TUESDAY, Dec. 4 (HealthDay ... spotted patients at highest risk of cardiac arrest or ... researchers report. , "This is important because past studies, ... people at risk," said study lead author Dr. Derek ...
... M.D., Chair of,Neurosurgery at Yale University School of ... American Epilepsy Society (AES), during the,organization,s 61st annual ... physicians and scientists who study and treat epilepsy., ... surgical treatment of,neurological diseases causing epilepsy. He developed ...
Cached Medicine News:Health News:Kaiser Permanente Opens 15th Medical Facility in Georgia 2Health News:Statement on Executive Life of New York Matter 2Health News:Sinusitis Treatments Found Ineffective 2Health News:Sinusitis Treatments Found Ineffective 3Health News:Liver transplant offers survival benefits for patients of all sizes 2Health News:Liver transplant offers survival benefits for patients of all sizes 3Health News:2-in-1 Test Signals Risk After Heart Attack 2Health News:2-in-1 Test Signals Risk After Heart Attack 3
... 20-dione) is a C21 steroid hormone containing ... between C-4 and C-5 (?4).,This steroid hormone ... conjunction with estrogens, regulates,the accessory organs during ... important in preparing the,endometrium for the implantation ...
... The test kit is an enzyme ... format with a liquid phase,incubation, designed ... in serum. The microplate is coated,with ... added to anti-rabbit antibody-coated wells, along ...
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease...
ACTH EIA Hypertension / Cardiac Evaluation, Cardiovascular 021-SDX018...
Medicine Products: